Antiverse closes $9.3M Series A to tackle undruggable targets
Antiverse, a biotechnology startup focused on next‑generation antibody discovery, has raised $9.3 million in Series A funding to accelerate the development of therapeutic antibodies against disease targets that have long been considered undruggable.
The fresh capital will be used to advance the company’s proprietary platform, which combines AI‑driven antibody design with high‑throughput laboratory validation to identify candidates for complex and previously inaccessible targets.
AI‑powered antibody discovery at the core
Antiverse is building a data‑rich engine that models how antibodies bind to antigens, enabling the rapid design and optimization of novel biologics. By integrating machine learning, structural biology and experimental screening, the company aims to dramatically shorten the traditional discovery timeline.
This approach is particularly relevant for targets that have resisted conventional small‑molecule drugs, such as certain membrane proteins, protein‑protein interactions and highly dynamic molecular structures. By focusing on these challenging mechanisms, Antiverse is positioning itself within a fast‑growing segment of biologic therapeutics.
Expanding pipeline and partnerships
The Series A funding will support expansion of Antiverse‘s internal pipeline of antibody programs and deepen collaborations with pharmaceutical and biotech partners. The company plans to invest in additional automation, data acquisition and computational infrastructure to scale its discovery efforts.
Industry observers note that the ability to systematically address historically undruggable targets could unlock new treatment options across oncology, immunology and rare diseases. With this new round, Antiverse joins a growing cohort of startups using AI and advanced protein engineering to reshape how antibody medicines are discovered and developed.
As pressure mounts on the pharmaceutical sector to deliver more precise and effective therapies, platforms like that of Antiverse are expected to play an increasingly central role in the next wave of biopharmaceutical innovation.